Welcome to our dedicated page for Prime Medicine SEC filings (Ticker: PRME), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Prime Medicine, Inc. SEC filings document the biotechnology company's financial results, pipeline disclosures, governance matters and material events tied to its Prime Editing programs. Recent Form 8-K filings include Item 2.02 results releases, Regulation FD corporate presentations and Item 5.02 executive appointment disclosures, with exhibits summarizing business highlights for PM577 in Wilson Disease, PM647 in Alpha-1 Antitrypsin Deficiency and PM359 in chronic granulomatous disease.
Proxy materials disclose annual meeting matters, director elections, auditor ratification, executive compensation and equity-plan information. Together, the filings provide formal records of PRME's public-company governance, disclosure controls, capital and compensation arrangements, and regulatory-development communications for its genetic-medicine pipeline.
Prime Medicine, Inc. (PRME) – Form 4 insider transaction
Director and 10% owner David R. Liu disclosed the purchase of 21,000 shares of Prime Medicine common stock on 23-Jun-2025. The trade was executed under a previously adopted Rule 10b5-1 plan dated 3-Mar-2025, indicating it was pre-scheduled rather than opportunistic.
The weighted-average purchase price was $2.162 per share, with individual trades occurring between $2.06 – $2.25. Following the transaction, Liu’s direct ownership increased to 20,219,945 shares, an incremental addition of roughly 0.10 % to his existing stake.
No derivative securities were reported, and no sales occurred. While the absolute dollar value of the purchase (~$45,400) is modest relative to Liu’s overall holding, insider buying—especially by a high-ownership director—can be interpreted as a vote of confidence in the company’s prospects at current price levels.